Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome
Sponsor: Uppsala University
Summary
This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and who are on respirator/ventilator (used synonymously in this protocol) support due to respiratory insufficiency with or without concomitant circulatory problems, will be included and treated with a single dose of KI-MSC-PL-205.
Official title: Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome Validation of Mechanistic Pathways and Clinical Efficacy
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2020-06-17
Completion Date
2026-03-30
Last Updated
2025-04-25
Healthy Volunteers
No
Conditions
Interventions
Mesenchymal Stromal Stem Cells - KI-MSC-PL-205
Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
Locations (1)
Uppsala University Hospital
Uppsala, Sweden